CSG 50 State Scan Research Series

The Biotech Frontier

How States are Partnering with Industry to Advance Patient Care and Biotechnology

Table of Contents

Section 1: Executive Summary

Executive Summary

Section 2: The State of the States: Patient Care, Pharmaceuticals, and Biotechnology

Section 2.a: Relevance and Public Concern

Section 2.b: State Legislation and Legislators’ Social Media Activity

Section 2.c: Providing Quality Patient Care for Constituents

Section 3: The Role of States in Improving Patient Care – Engaging the Pharmaceuticals Sector and Fostering Biotechnology Innovation

Section 3.a: Priorities in the Healthcare, Pharmaceuticals, and Biotech Industries for State Governments

Section 3.b: Trends in the Cost of Providing High-Quality Healthcare to State Residents

Section 3.c: How Can State Leaders Direct Resources to Clinical Medical Education Facilities and Research Labs?

Section 4: Case Studies of Successful Biotechnology Hubs

Section 4.a: Maryland-Virginia-District of Columbia BioHealth Capital Region, Massachusetts’ Boston Cambridge Area, and Pennsylvania

Section 4.b: North Carolina’s Raleigh-Durham-Chapel Hill Research Triangle and Texas’ Dallas-Houston-Austin “Texaplex” Area

Section 4.c: California’s Bay Area and Washington State

Section 4.d: Wisconsin-Illinois-Indiana Chicagoland Area and Minnesota’s Medical Alley

Section 5: State Political Contexts and Resources for Patient Care, Pharmaceuticals, and Biotechnology

Section 5a: State Tax Incentives

Section 5b: Biotechnology Companies per State

Section 5c: NIH/Federal Funding

Section 5d: Talent Pool – Universities/Students

Section 5e: Workforce

Section 5f: Venture Capital Resources

Section 5g: BioPharma Research and Innovation

Section 6: Best Practices and Considerations for State Policy

Lessons Learned by Leading States